These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 36568559)

  • 21. Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program.
    Neuen BL; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Blais J; Li Q; Jardine MJ; Perkovic V; Wheeler DC
    Am J Kidney Dis; 2021 Jan; 77(1):23-34.e1. PubMed ID: 32971190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prognosis of subjects showing a reduced estimated glomerular filtration rate without albuminuria in Japanese patients with type 2 diabetes: a cohort study for diabetic kidney disease.
    Ito H; Antoku S; Izutsu T; Kusano E; Matsumoto S; Yamasaki T; Mori T; Togane M
    Clin Exp Nephrol; 2020 Nov; 24(11):1033-1043. PubMed ID: 32734506
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison between urine albumin-to-creatinine ratio and urine protein dipstick testing for prevalence and ability to predict the risk for chronic kidney disease in the general population (Iwate-KENCO study): a prospective community-based cohort study.
    Koeda Y; Tanaka F; Segawa T; Ohta M; Ohsawa M; Tanno K; Makita S; Ishibashi Y; Itai K; Omama SI; Onoda T; Sakata K; Ogasawara K; Okayama A; Nakamura M
    BMC Nephrol; 2016 May; 17(1):46. PubMed ID: 27169575
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Albuminuria and Allograft Failure, Cardiovascular Disease Events, and All-Cause Death in Stable Kidney Transplant Recipients: A Cohort Analysis of the FAVORIT Trial.
    Weiner DE; Park M; Tighiouart H; Joseph AA; Carpenter MA; Goyal N; House AA; Hsu CY; Ix JH; Jacques PF; Kew CE; Kim SJ; Kusek JW; Pesavento TE; Pfeffer MA; Smith SR; Weir MR; Levey AS; Bostom AG
    Am J Kidney Dis; 2019 Jan; 73(1):51-61. PubMed ID: 30037726
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence for two distinct phenotypes of chronic kidney disease in individuals with type 1 diabetes mellitus.
    Penno G; Russo E; Garofolo M; Daniele G; Lucchesi D; Giusti L; Sancho Bornez V; Bianchi C; Dardano A; Miccoli R; Del Prato S
    Diabetologia; 2017 Jun; 60(6):1102-1113. PubMed ID: 28357502
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urinary Biomarkers of Tubular Damage Are Associated with Mortality but Not Cardiovascular Risk among Systolic Blood Pressure Intervention Trial Participants with Chronic Kidney Disease.
    Jotwani VK; Lee AK; Estrella MM; Katz R; Garimella PS; Malhotra R; Rifkin DE; Ambrosius W; Freedman BI; Cheung AK; Raphael KL; Drawz P; Neyra JA; Oparil S; Punzi H; Shlipak MG; Ix JH;
    Am J Nephrol; 2019; 49(5):346-355. PubMed ID: 30939472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cognitive Function and Kidney Disease: Baseline Data From the Systolic Blood Pressure Intervention Trial (SPRINT).
    Weiner DE; Gaussoin SA; Nord J; Auchus AP; Chelune GJ; Chonchol M; Coker L; Haley WE; Killeen AA; Kimmel PL; Lerner AJ; Oparil S; Saklayen MG; Slinin YM; Wright CB; Williamson JD; Kurella Tamura M;
    Am J Kidney Dis; 2017 Sep; 70(3):357-367. PubMed ID: 28606731
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.
    Wheeler DC; Stefánsson BV; Jongs N; Chertow GM; Greene T; Hou FF; McMurray JJV; Correa-Rotter R; Rossing P; Toto RD; Sjöström CD; Langkilde AM; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2021 Jan; 9(1):22-31. PubMed ID: 33338413
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease.
    Mann JFE; Fonseca V; Mosenzon O; Raz I; Goldman B; Idorn T; von Scholten BJ; Poulter NR
    Circulation; 2018 Dec; 138(25):2908-2918. PubMed ID: 30566006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High risks of all-cause and cardiovascular deaths in apparently healthy middle-aged people with preserved glomerular filtration rate and albuminuria: A prospective cohort study.
    Ohsawa M; Fujioka T; Ogasawara K; Tanno K; Okamura T; Turin TC; Itai K; Ogawa A; Yoshida Y; Omama S; Onoda T; Nakamura M; Makita S; Ishibashi Y; Tanaka F; Kuribayashi T; Ohta M; Sakata K; Okayama A
    Int J Cardiol; 2013 Dec; 170(2):167-72. PubMed ID: 24211064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diverging association of reduced glomerular filtration rate and albuminuria with coronary and noncoronary events in patients with type 2 diabetes: the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study.
    Solini A; Penno G; Bonora E; Fondelli C; Orsi E; Arosio M; Trevisan R; Vedovato M; Cignarelli M; Andreozzi F; Nicolucci A; Pugliese G;
    Diabetes Care; 2012 Jan; 35(1):143-9. PubMed ID: 22124714
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intensive Blood Pressure Treatment Reduced Stroke Risk in Patients With Albuminuria in the SPRINT Trial.
    Leitão L; Soares-Dos-Reis R; Neves JS; Baptista RB; Bigotte Vieira M; Mc Causland FR
    Stroke; 2019 Dec; 50(12):3639-3642. PubMed ID: 31637971
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chronic kidney disease categories and renal-cardiovascular outcomes in type 2 diabetes without prevalent cardiovascular disease: a prospective cohort study (JDDM25).
    Yokoyama H; Araki S; Haneda M; Matsushima M; Kawai K; Hirao K; Oishi M; Sugimoto K; Sone H; Maegawa H; Kashiwagi A;
    Diabetologia; 2012 Jul; 55(7):1911-8. PubMed ID: 22476921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Albuminuric and non-albuminuric chronic kidney disease in type 1 diabetes: Association with major vascular outcomes risk and all-cause mortality.
    Garofolo M; Russo E; Miccoli R; Lucchesi D; Giusti L; Sancho-Bornez V; Daniele G; Del Prato S; Penno G
    J Diabetes Complications; 2018 Jun; 32(6):550-557. PubMed ID: 29705091
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical impact of albuminuria and glomerular filtration rate on renal and cardiovascular events, and all-cause mortality in Japanese patients with type 2 diabetes.
    Wada T; Haneda M; Furuichi K; Babazono T; Yokoyama H; Iseki K; Araki S; Ninomiya T; Hara S; Suzuki Y; Iwano M; Kusano E; Moriya T; Satoh H; Nakamura H; Shimizu M; Toyama T; Hara A; Makino H;
    Clin Exp Nephrol; 2014 Aug; 18(4):613-20. PubMed ID: 24132561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Albuminuric and non-albuminuric reduced eGFR phenotypes in youth with type 1 diabetes: Factors associated with cardiometabolic risk.
    Di Bonito P; Mozzillo E; Rosanio FM; Maltoni G; Piona CA; Franceschi R; Ripoli C; Ricciardi MR; Tornese G; Arnaldi C; Iovane B; Iafusco D; Zanfardino A; Suprani T; Savastio S; Cherubini V; Tiberi V; Piccinno E; Schiaffini R; Delvecchio M; Casertano A; Maffeis C; Franzese A;
    Nutr Metab Cardiovasc Dis; 2021 Jun; 31(7):2033-2041. PubMed ID: 34083127
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis.
    Mahmoodi BK; Matsushita K; Woodward M; Blankestijn PJ; Cirillo M; Ohkubo T; Rossing P; Sarnak MJ; Stengel B; Yamagishi K; Yamashita K; Zhang L; Coresh J; de Jong PE; Astor BC;
    Lancet; 2012 Nov; 380(9854):1649-61. PubMed ID: 23013600
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure: A Secondary Analysis of EMPEROR-Pooled.
    Ferreira JP; Zannad F; Butler J; Filippatos G; Pocock SJ; Brueckmann M; Steubl D; Schueler E; Anker SD; Packer M
    JAMA Cardiol; 2022 Nov; 7(11):1148-1159. PubMed ID: 36129693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Can patiromer allow for intensified renin-angiotensin-aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled trial: MorphCKD.
    Mårup FH; Peters CD; Christensen JH; Birn H
    BMJ Open; 2022 Feb; 12(2):e057503. PubMed ID: 35190442
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial.
    Ando K; Ohtsu H; Uchida S; Kaname S; Arakawa Y; Fujita T;
    Lancet Diabetes Endocrinol; 2014 Dec; 2(12):944-53. PubMed ID: 25466242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.